Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2019

24.04.2019 | Breast Oncology

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters

verfasst von: Harry D. Bear, MD, PhD, Kandace P. McGuire, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

The transition from axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB) has been a major advance over the past 30 years, leading to decreased morbidity of breast cancer treatment.1,2 Similarly, demonstrations that neoadjuvant systemic therapy (NST) is equivalent to adjuvant therapy have paved the way to de-escalation of local and regional therapies, despite some concerns about possible increased risk of local recurrence in the breast.38 For example, now NST often is used to avoid total mastectomy, to reduce the magnitude of partial mastectomies and potentially to avoid ALND and/or regional nodal irradiation, even in patients with clinically positive nodes at the time of diagnosis.6,9,10 The use of SLNB in place of ALND after NST has been widely accepted for patients with clinically negative nodes at presentation, but the same approach has been more controversial for patients with clinically and pathologically proven positive nodes. Current NCCN guidelines regarding surgical lymph node staging after NST state that if axillary node imaging or needle biopsy is negative, then SLN should preferably be performed after NST.11 It also notes that NST “may allow SLNB alone if a positive axilla is cleared with therapy.” ASCO guidelines from 2016 suggest that SLNB may be offered to patients who receive NST but suggest caution for patients with large or bulky metastatic axillary nodes.12 Conversion of positive to negative nodes is more likely to occur with triple negative or HER-2+ breast cancers, and multiple studies have shown that neoadjuvant chemotherapy results in a fairly consistent conversion rate from clinically positive nodes to pathologically negative nodes in the range of 40%.10,1317
Literatur
1.
2.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentral Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.CrossRefPubMed Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.CrossRefPubMed
4.
Zurück zum Zitat Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. JNCI Mongraphs. 2001;30:96–102.CrossRef Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. JNCI Mongraphs. 2001;30:96–102.CrossRef
5.
Zurück zum Zitat Early Breast Cancer Trial Collab Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.CrossRef Early Breast Cancer Trial Collab Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.CrossRef
6.
Zurück zum Zitat Ataseven B, von MG. The impact of neoadjuvant treatment on surgical options and outcomes. Ann Surg Oncol. 2016;23:3093–9. Ataseven B, von MG. The impact of neoadjuvant treatment on surgical options and outcomes. Ann Surg Oncol. 2016;23:3093–9.
7.
Zurück zum Zitat Kaufmann M, von MG, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16. Kaufmann M, von MG, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.
8.
Zurück zum Zitat Kantor O, Ajmani G, Wang C-H, et al. The shifting paradigm for breast cancer surgery in patients udergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:164–72.CrossRefPubMed Kantor O, Ajmani G, Wang C-H, et al. The shifting paradigm for breast cancer surgery in patients udergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:164–72.CrossRefPubMed
9.
Zurück zum Zitat Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220:1063–9.CrossRefPubMed Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220:1063–9.CrossRefPubMed
10.
Zurück zum Zitat Puig CA, Hoskin TL, Day CN, et al. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: A National Cancer Data Base Study. Ann Surg Oncol. 2017;24:1242–50.CrossRefPubMed Puig CA, Hoskin TL, Day CN, et al. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: A National Cancer Data Base Study. Ann Surg Oncol. 2017;24:1242–50.CrossRefPubMed
12.
Zurück zum Zitat Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:561–4.CrossRefPubMed Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:561–4.CrossRefPubMed
13.
Zurück zum Zitat Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.CrossRefPubMed Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.CrossRefPubMed
14.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.CrossRefPubMedPubMedCentral Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Koolen BB, Valdes Olmos RA, Wesseling J, et al. Early assessment of axillary response with (1)(8)F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227–35.CrossRefPubMed Koolen BB, Valdes Olmos RA, Wesseling J, et al. Early assessment of axillary response with (1)(8)F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227–35.CrossRefPubMed
16.
Zurück zum Zitat Park TS, Thomas SM, Rosenberger LH, et al. The association of extent of axillary surgery and survival in women with N2-3 invasive breast cancer. Ann Surg Oncol. 2018;25:3019–29.CrossRefPubMedPubMedCentral Park TS, Thomas SM, Rosenberger LH, et al. The association of extent of axillary surgery and survival in women with N2-3 invasive breast cancer. Ann Surg Oncol. 2018;25:3019–29.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hieken TJ, Boughey JC, Jones KN, et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20:3199–204.CrossRefPubMed Hieken TJ, Boughey JC, Jones KN, et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20:3199–204.CrossRefPubMed
18.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMed Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMed
19.
Zurück zum Zitat Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMed Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMed
20.
Zurück zum Zitat Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59.CrossRefPubMed Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59.CrossRefPubMed
21.
Zurück zum Zitat von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.CrossRef von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.CrossRef
22.
Zurück zum Zitat Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015;22:1434–40.CrossRefPubMed Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015;22:1434–40.CrossRefPubMed
23.
Zurück zum Zitat Fernandez LJ, Bear HD. Axillary node management in patients receiving neoadjuvant chemotherapy. Curr Breast Cancer Rep 2015;7:30–6.CrossRef Fernandez LJ, Bear HD. Axillary node management in patients receiving neoadjuvant chemotherapy. Curr Breast Cancer Rep 2015;7:30–6.CrossRef
24.
Zurück zum Zitat Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.CrossRefPubMed Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.CrossRefPubMed
25.
Zurück zum Zitat Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta-analysis. Acad Radiol. 2009;16:551–63.CrossRefPubMed Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta-analysis. Acad Radiol. 2009;16:551–63.CrossRefPubMed
26.
Zurück zum Zitat van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124–30.CrossRefPubMed van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124–30.CrossRefPubMed
27.
Zurück zum Zitat Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.CrossRefPubMedPubMedCentral Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82.CrossRefPubMed Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82.CrossRefPubMed
29.
Zurück zum Zitat Siso C, de TJ, Esgueva-Colmenarejo A, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol 2018; 25:784–91. Siso C, de TJ, Esgueva-Colmenarejo A, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol 2018; 25:784–91.
30.
Zurück zum Zitat Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269:432–42.CrossRefPubMed Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269:432–42.CrossRefPubMed
31.
Zurück zum Zitat Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802–7.CrossRefPubMed Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802–7.CrossRefPubMed
32.
Zurück zum Zitat Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol 2015; 22:377–382.CrossRefPubMed Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol 2015; 22:377–382.CrossRefPubMed
33.
Zurück zum Zitat Coufal O, Zapletal O, Gabrielova L, et al. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study. Rozhl Chir 2018; 97:551–557.PubMed Coufal O, Zapletal O, Gabrielova L, et al. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study. Rozhl Chir 2018; 97:551–557.PubMed
34.
Zurück zum Zitat Jung S-Y, Han JH, Lee E-G, et al. Comparison of sentinel lymph node biopsy using the dual method of indocyanine green fluorescence plus radioisotope versus radioisotope versus radioisotope only in breast cancer patients after neoadjuvant chemotherapy: a prospective, randomized, open-label, single center phase 2 trial. Ann Surg Oncol. 2019 (in press). Jung S-Y, Han JH, Lee E-G, et al. Comparison of sentinel lymph node biopsy using the dual method of indocyanine green fluorescence plus radioisotope versus radioisotope versus radioisotope only in breast cancer patients after neoadjuvant chemotherapy: a prospective, randomized, open-label, single center phase 2 trial. Ann Surg Oncol. 2019 (in press).
35.
Zurück zum Zitat Alliance 11202: a randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. 2019. Available at:https://clinicaltrials.gov/ct2/show/NCT01901094. Accessed 7 March 2019. Alliance 11202: a randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. 2019. Available at:https://​clinicaltrials.​gov/​ct2/​show/​NCT01901094.​ Accessed 7 March 2019.
Metadaten
Titel
Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters
verfasst von
Harry D. Bear, MD, PhD
Kandace P. McGuire, MD
Publikationsdatum
24.04.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07401-z

Weitere Artikel der Ausgabe 8/2019

Annals of Surgical Oncology 8/2019 Zur Ausgabe

Health Services Research and Global Oncology

Changing Trends in Industry Funding for Surgical Oncologists

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.